Inscripta adds $30M to series C to speed use of its gene editing tools

Inscripta Inc. (Boulder, Colo.) added an untranched $30 million to its series C round to accelerate development and adoption of its CRISPR gene-editing enzymes and

Read the full 251 word article

User Sign In